Phenotyping of Urinary Urgency Patients Without Urgency Incontinence, and Their Comparison to Urgency Incontinence Patients: Findings From the LURN Study
By: H. Henry Lai, MD*; Jonathan B. Wiseman, MS; Margaret E. Helmuth, MA; Abigail R. Smith, PhD; Cindy L. Amundsen, MD; Anne P. Cameron, MD; Alexander P. Glaser, MD; Whitney K. Hendrickson, MD; Ziya Kirkali, MD; Kimberly Kenton, MD, MS
Open for Submissions
The AUA will publish its third annual “Celebrating Diversity with the AUA” focus issue in April 2023. We are holding an open call for submissions on all content related to diversity, equity and inclusion in urology. We welcome manuscripts on a broad range of topics. Submissions are due no later than February 3, 2023, at 12 midnight.
Transurethral Resection of Bladder Tumor vs Chemoablation for Nonmuscle-invasive Bladder Cancer
By: Taylor Parisse, BA*; Katy Reines, MD*; Ramsankar Basak, PhD; Dana Mueller, MS; Randall Teal, MA; Maihan B. Vu, DrPH, MPH; Jessica Carda-Auten, MPH; Kathryn Stein; Kara Giannone, MPH; Robert Lipman; Angela B. Smith, MD, MS
Robotic Level IV Inferior Vena Cava Thrombectomy Using an Intrapericardial Control Technique
By: Qingbo Huang, MD; Guodong Zhao, MD; Yonghui Chen, MD; Peng Wu, MD; Shuanglei Li, MD; Cheng Peng, MD; Kan Liu, MD; Hongkai Yu, MD; Yubo Gao, MD; Cangsong Xiao, MD; Qiang Fu, MD; Hao Shen, MD; Qiuyang Li, MD; Nan Li, MD; Haiyi Wang, MD; Xeng Inn Fam, MD; Baojun Wang, MD; Rong Liu, MD, PhD; Xu Zhang, MD, PhD; Xin Ma, MD, PhD
Cancer-based Genetic Testing in Healthy U.S. Adults vs Those With Prostate or Breast/Ovarian Cancer
By: Sameer Thakker, MD; Stacy Loeb, MD; Veda N. Giri, MD; Marc A. Bjurlin, MD; Richard S. Matulewicz, MD
Bladder and Kidney Cancer Diagnosis and Survival Increase With Medicare Eligibility at Age 65
By: Timothy D. Shu, MD; Megan C. Prunty, MD; Raymond Pominville, MD; Danly Omil-Lima, MD; Alberto A. Castro Bigalli, MD; Alexander Kutikov, MD; Laura Bukavina, MD, MPH; Adam C. Calaway, MD, MPH; Sarah C. Markt, ScD, MPH
January Extra 2023
The January Extra issue of AUANews is online! Read every article, search by topic and other keywords, all from the comfort of your digital device!
View by Topics
Top 4 Articles
Antibiotic Therapy for Common Stone Procedures: What Is the Optimal Duration?
By: Shane Kronstedt, BS; Jonathan E. Katz, MD; Roger L. Sur, MD
Shock Wave Therapy for Erectile Dysfunction: Patterns of Care and Efficacy
By: Juan J. Andino, MD, MBA; Jeffrey C. Morrison, MD; Sriram Eleswarapu, MD; Jesse N. Mills, MD
Disproportionate Effects of Prostate Cancer in Black Men: The ConDUC Initiative
By: Arthur L. Burnett, MD, MBA
Thulium Lasers Blast into the World of Endourology
By: Arshia Aalami Harandi, MS; Alexander Small, MD
Current first-line treatment for advanced urothelial carcinoma (aUC) is platinum-based (preferably cisplatin) combination chemotherapy. In the second-line setting, pembrolizumab immunotherapy is standard. Taxane chemotherapy had shown single-agent activity. We sought to evaluate the combination of nab-paclitaxel (NAB) and pembrolizumab in patients with cisplatin-ineligible or platinum-refractory aUC.
Out of Office
Have you ever wondered what your favorite urologists do in their spare time? From piloting planes to living on a fully operational farm, learn more about their stories here.
Use "Celebrating Diversity with the AUA" focus issues as resources for years to come.
These Highlight Issues feature state-of-the-art research in the advancement of treatment of prostate cancer.
These Highlight Issues feature state-of-the-art reserch in the advancement of treatment of kidney stones.